reason report
bottom line deliv revenue touch expect
ep slightli ahead consensu management
reiter cc revenue growth guidanc busi segment revenue
adj ep rang decreas due paclitaxel-co devic fx
key question like area focu call
rev/ep risk exposur could paclitaxel regulatori market
pressur extend next year meantim suspect adj ep
number reset light revis guidanc listen
call think long-term impact paclitaxel pressur
bd intervent biz whether portion biz off-set
keep grower intermedi term reiter mp
call start et dial password
 tax off-set ep beat us/consensu
deliv sale came consensu
consensu org revenue growth y/i
cc miss us/consensu y/i cc turn
biz segment bd medic cc largest underperform
bd life scienc cc bd intervent cc
roughli in-lin model bd medic impact
medic deliveri solut md unit reflect tough comp
distributor inventori adjust us bd life scienc diagnost
system unit reflect tough comp due strong flu area
under-perform rel consensu model
accur gm consensu
vs ebita mgn miss us/consensu
ultim better expect interest income/expens
higher-than-expect tax rate off-set rel model adj
ep beat us/consensu
medic suppli devic
pleas refer page import disclosur price chart analyst certif
organ cc guid reiter management reiter
org cc revenue growth incl bard revenue
growth cc life scienc revenue growth cc
intervent revenue growth cc vs cc prior management
re-affirmed strong acceler similar fx abat
new product gain steam revenue synergi ramp previous
commun call
adj ep outlook reduc adj ep guidanc
decreas previous issu guidanc due recent regulatori
market pressur relat paclitaxel-co devic lutonix
management estim headwind greater fx
headwind -- project headwind vs prior
management also lower gm ebita margin
respect listen addit commentari management
may provid cadenc
thing listen call mgmt thought
upcom fda panel schedul mid-jun time potenti
upcom data analys potenti rev/ep risk exposur
paclitaxel regulatori market pressur extend next year
track area busi management
confid off-set lower expect bd intervent
busi suspect primarili due peripher intervent
dollar million except ep
margin sale
compani report factset consensu svb leerink llc estim
